In Silico Analysis of Post-COVID-19 Condition (PCC) Associated SNP rs9367106 Predicts the Molecular Basis of Abnormalities in the Lungs and Brain Functions.

Publication date: Jul 11, 2025

Long- or post-COVID-19 syndrome, which is also designated by WHO as Post COVID-19 Condition (PCC), is characterized by the persistent symptoms that remain after recovery from SARS-CoV-2 infection. A worldwide consortium of Long COVID-19 Host Genetics Initiative (Long COVID-19 HGI) identified an SNP rs9367106 (G>C; chr6:41,515,652, GRCh38, p = 1. 76 cD7 10, OR = 1. 63, 95% CI: 1. 40-1. 89) that is associated with PCC. Unraveling the functional significance of this SNP is of prime importance to understanding the development of the PCC phenotypes and their therapy. Here, in Silico, I explored how the risk allele of this SNP alters the functional mechanisms and molecular pathways leading to the development of PCC phenotypes. Bioinformatic methods include physical interactions using HI-C and Chia-PET analysis, Transcription Factors (TFs) binding ability, RNA structure modeling, epigenetic, and pathway analysis. This SNP resides within two long RNA genes, LINC01276 and FOXP4-AS1, and is located at ~31 kb upstream of a transcription factor FOXP4. This DNA region, including this SNP, physically interacts with FOXP4-AS1 and FOXP4, implying that this regulatory SNP could alter the normal cellular function of FOXP4-AS1 and FOXP4. Furthermore, rs9367106 is in eQTL with the FOXP4 gene in lung tissue. rs9367106 carrying DNA sequences act as distant enhancers and bind with several transcription factors (TFs) including YY1, PPAR-α, IK-1, GR-α, and AP2αA. The G>C transition extensively modifies the RNA structure that may affect the TF bindings and enhancer functions to alter the interactions and functions of these RNA molecules. This SNP also includes an ALU/SINE sequence and alteration of which by the G>C transition may prevent IFIH1/MDA5 activation, leading to suppression of host innate immune responses. LINC01276 targets the MED20 gene that expresses mostly in brain tissues, associated with sleep disorders and basal ganglia abnormalities similar to some of the symptoms of PCC phenotypes. Taken together, G>C transition of rs9367601 may likely alter the function of all three genes to explain the molecular basis of developing the long-term symptomatic abnormalities in the lungs and brain observed after COVID-19 recovery.

Open Access PDF

Concepts Keywords
Allele Brain
Bioinformatic Computational Biology
Med20 Computer Simulation
Sleep COVID-19
enhancer
FOXP4
Humans
LINC01276
Lung
polymorphism
Polymorphism, Single Nucleotide
post-COVID-19 condition
RNA, Long Noncoding
RNA, Long Noncoding
SARS-CoV-2
sleep disorder
transcription factor
Transcription Factors
Transcription Factors

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Factor IX Complex (Human)
disease MESH Abnormalities
disease MESH syndrome
pathway REACTOME SARS-CoV-2 Infection
disease MESH Long COVID
disease IDO host
disease MESH sleep disorders
drug DRUGBANK Coenzyme M
disease MESH infection
drug DRUGBANK Methylergometrine
disease MESH depression
drug DRUGBANK Serotonin
disease MESH inflammation
disease MESH mitochondrial dysfunction
disease MESH critical illness
pathway KEGG Viral replication
drug DRUGBANK Pegademase bovine
disease MESH Hepatocellular carcinoma
pathway KEGG Hepatocellular carcinoma
disease MESH osteosarcoma
disease IDO cell
disease MESH adenocarcinoma
disease MESH sensorineural hearing loss
disease MESH language disorder
disease IDO replication
pathway REACTOME Innate Immune System
disease MESH viral infection
disease IDO production
disease MESH cancers
disease IDO blood
disease MESH brain disorders
disease MESH liver cancers
disease IDO assay
drug DRUGBANK Ademetionine
disease MESH morbidities
disease MESH complications
disease MESH thromboinflammation
disease MESH Respiratory Failure
disease IDO susceptibility
pathway REACTOME Apoptosis
drug DRUGBANK Calcium Carbonate
drug DRUGBANK Guanosine
disease MESH Allergy
pathway REACTOME Immune System
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Carboxyamidotriazole
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease MESH Death
disease MESH lung adenocarcinoma
disease MESH congenital diaphragmatic hernia
disease MESH language delays
disease MESH congenital abnormalities
pathway REACTOME Deubiquitination

Original Article

(Visited 1 times, 1 visits today)